Anti-Mouse NKG2A/C/E - Purified in vivo PLATINUM™ Functional Grade

Contact us
Leinco Technologies
Product Code: LEI-N560
Product Group: Primary Antibodies
CodeSizePrice
LEI-N560-1.0mg1 mg£283.00
Quantity:
LEI-N560-5.0mg5 mg£456.00
Quantity:
LEI-N560-25mg25 mg£1,335.00
Quantity:
LEI-N560-50mg50 mg£1,938.00
Quantity:
LEI-N560-100mg100 mg£2,741.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rat
Antibody Isotype: IgG2a κ
Antibody Clonality: Monoclonal
Antibody Clone: 20D5
Regulatory Status: RUO
Target Species: Mouse
Applications:
  • Blocking
  • Flow Cytometry
  • Immunohistochemistry (IHC)
  • In Vivo Assay
Shipping:
2-8°C
Storage:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Further Information

Antigen Distribution:
NKG2A/C/E is expressed on NK cells, NKT cells, and activated CD8 T cells.
Concentration:
? 5.0 mg/ml
Conjugate/Tag/Label:
Purified in vivo Functional Grade, in vivo PLATINUM™
Format:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
CHO transfected cells expressing the C57BL/6 allele of NKG2A and CD94
Long Description:
NKG2A/C/E antibody, clone 20D5, recognizes the NKG2A, NKG2C, and NKG2E isoforms (also known as CD159a, CD159c,m CD159e, respectively) of the NKG2 receptor, belonging to the C-type lectin-like family. NKG2 receptors are expressed at the cell surface as a heterodimer with CD94 and recognize the non-classical class I MHC-1 molecules HLA-E in humans and Qa-1 in mice1-4. NKG2A/C/E are expressed on natural killer (NK) cells, NKT cells, and activated CD8 T cells5-6. Engagement of NKG2A/CD94 transduces an inhibitory signal, blocking NK and CD8 T cell cytotoxicity and promoting self-tolerance7. In contrast, NKG2C/CD94 and NKGE/CD94 are activating receptors8 and bind with lower affinity to HLA-E9. Cancer cells frequently overexpress HLA-E to protect against NK/CD8 T cell killing, and blocking NKG2 receptors in mice promotes anti-tumor immunity and may enhance the cytotoxic potential of other therapeutic antibodies10,11. The NKG2 receptor antibody monalizumab is currently in phase III clinical trials (INTERLINK-1) in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Purity:
?98% monomer by analytical SEC, >95% by SDS Page
Target:
NKG2a

References

1. Vance R.E., et al. (1998) J. Exp. Med. 188:1841?1848 2. Braud VM, et al. (1998) Nature. 391(6669):795-9 3. Vance RE, et al. (1999) J Exp Med. 190(12):1801-1812 4. Brooks AG, et al. (1997) J Exp Med. 185(4):795-800 5. Gunturi A, Berg RE, Forman J. (2004) Immunol Res. 30(1):29-34 6. Bertone S, et al. (1999) Eur J Immunol. 29(1):23-9 7. Le Dr?an E, et al. (1998) Eur J Immunol. 28(1):264-76 8. Lanier LL, et al. (1998) Immunity. 8(6):693-701 9. Kaiser BK, et al. (2005) J Immunol. 174(5):2878-84 10. Andr? P, Denis C, Soulas C, et al. (2018) Cell. 175(7):1731-1743.e13 11. van Montfoort N, Borst L, Korrer MJ, et al. (2018) Cell. 175(7):1744-1755.e15